Ivar Sjaastad
Overview
Explore the profile of Ivar Sjaastad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
203
Citations
3404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Andreassen K, Rixon C, Hansen M, Hauge-Iversen I, Zhang L, Sadredini M, et al.
Am J Physiol Heart Circ Physiol
. 2023 Apr;
324(6):H881-H892.
PMID: 37115627
The effect of exercise on disease development in hypertrophic cardiomyopathy (HCM) genotype-positive individuals is unresolved. Our objective was to test the effect of exercise training initiated before phenotype development on...
12.
Tonnessen T, Ueland T, Ahmed M, Attramadal H, Sjaastad I, Vinge L
Basic Clin Pharmacol Toxicol
. 2023 Mar;
132(6):551-555.
PMID: 36946742
No abstract available.
13.
Berger S, Witczak B, Reiseter S, Schwartz T, Andersson H, Hetlevik S, et al.
Rheumatol Int
. 2023 Mar;
43(6):1055-1065.
PMID: 36933069
We aimed to identify cardiac function in patients with established mixed connective tissue disease (MCTD). This was a cross-sectional case-control study of well-characterised MCTD patients who had previously been included...
14.
Skogestad J, Albert I, Hougen K, Lothe G, Lunde M, Eken O, et al.
Circulation
. 2023 Mar;
147(16):1221-1236.
PMID: 36876489
Background: Increasing SERCA2 (sarco[endo]-plasmic reticulum Ca ATPase 2) activity is suggested to be beneficial in chronic heart failure, but no selective SERCA2-activating drugs are available. PDE3A (phosphodiesterase 3A) is proposed...
15.
Marstein H, Witczak B, Godang K, Olarescu N, Schwartz T, Flato B, et al.
RMD Open
. 2023 Feb;
9(1).
PMID: 36828644
Objectives: In long-term juvenile dermatomyositis (JDM), altered adipose tissue distribution and subclinical cardiac dysfunction have been described. Our aims were to compare adipokine levels in patients with JDM after long-term...
16.
Rypdal K, Olav Melleby A, Robinson E, Li J, Palmero S, Seifert D, et al.
Commun Biol
. 2022 Dec;
5(1):1392.
PMID: 36539599
Heart failure is a major cause of morbidity and mortality worldwide, and can result from pressure overload, where cardiac remodelling is characterized by cardiomyocyte hypertrophy and death, fibrosis, and inflammation....
17.
Haugsten Hansen M, Sadredini M, Hasic A, Anderson M, Sjaastad I, Stokke M
J Mol Cell Cardiol
. 2022 Dec;
175:49-61.
PMID: 36528076
Background: Available evidence suggest that Ca/calmodulin-dependent protein kinase type IIδ (CaMKIIδ) and reactive oxygen species (ROS) are important in early ischemia-reperfusion arrhythmias (IRA). Since ROS can activate CaMKIIδ by oxidation...
18.
Rixon C, Andreassen K, Shen X, Erusappan P, Almaas V, Palmero S, et al.
ESC Heart Fail
. 2022 Nov;
10(2):858-871.
PMID: 36444917
Aims: Familial hypertrophic cardiomyopathy (HCM) is the most common form of inherited cardiac disease. It is characterized by myocardial hypertrophy and diastolic dysfunction, and can lead to severe heart failure,...
19.
Lunde I, Aronsen J, Olav Melleby A, Strand M, Skogestad J, Bendiksen B, et al.
Mol Biol Rep
. 2022 Oct;
49(12):11795-11809.
PMID: 36205855
Background: Cardiomyocyte hypertrophy is a hallmark of cardiac dysfunction in patients with aortic stenosis (AS), and can be triggered by left ventricular (LV) pressure overload in mice by aortic banding...
20.
Stole T, Lunde M, Shen X, Martinsen M, Lunde P, Li J, et al.
Front Cell Dev Biol
. 2022 Sep;
10:908126.
PMID: 36092718
In cardiac muscle, the ubiquitously expressed proteoglycan syndecan-4 is involved in the hypertrophic response to pressure overload. Protein kinase Akt signaling, which is known to regulate hypertrophy, has been found...